Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23922127 | 0.93 | CACNA1H (0.49) | CACNA1HCARM1PRMT6PRMT8ACE2 | |
| SCHEMBL7891824 | 0.87 | PAOX (0.40) | CACNA1HACE2PAOXALDH1A1KDM4E | |
| SCHEMBL28631927 | 0.85 | PAOX (0.43) | CACNA1HPAOXALDH1A1SIGMAR1 | |
| SCHEMBL26748675 | 0.84 | CACNA1H (0.44) | CACNA1HCARM1PRMT6PRMT8ACE2 | |
| SCHEMBL10245377 | 0.84 | CACNA1H (0.44) | CACNA1HCARM1PRMT6PRMT8ACE2 | |
| SCHEMBL19961023 | 0.84 | CARM1 (0.50) | CACNA1HCARM1PRMT6PRMT8ACE2 | |
| SCHEMBL10192177 | 0.84 | CARM1 (0.56) | CACNA1HCARM1PRMT6PRMT8ALDH1A1 | |
| SCHEMBL28644525 | 0.84 | PAOX (0.46) | CACNA1HPAOXALDH1A1SIGMAR1 | |
| SCHEMBL12262499 | 0.83 | CACNA1H (0.43) | CACNA1HCARM1PRMT6PRMT8ACE2 | |
| SCHEMBL26581818 | 0.83 | HDAC2 (0.36) | CACNA1HCARM1PRMT6PRMT8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453784-B | Method for removing acid gases from fluid streams | 巴斯夫欧洲公司 | 2024-09-13 | — | — | CN | claimed |
| EP-3927450-B1 | PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM WITH A LIQUID ABSORBENT COMPRISING A PIPERAZINE RING | BASF SE (DE) | 2023-06-07 | — | — | EP | claimed |
| CN-113453784-A | Process for removing acid gases from fluid streams | 巴斯夫欧洲公司 | 2021-09-28 | — | — | CN | claimed |
| US-12138583-B2 | Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring | BASF SE (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-113453784-B | Method for removing acid gases from fluid streams | 巴斯夫欧洲公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | CACNA1H 3129/4885CARM1 546/4885PRMT6 1642/4885 |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | CACNA1H 3216/4885CARM1 3615/4885PRMT6 2134/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CACNA1H 4499/4885CARM1 665/4885PRMT6 1432/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | CACNA1H 3537/4885CARM1 3029/4885PRMT6 1278/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | CACNA1H 3993/4885CARM1 1094/4885PRMT6 552/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | CACNA1H 1646/4885CARM1 2741/4885PRMT6 2203/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | CACNA1H 4104/4885CARM1 1397/4885PRMT6 567/4885 |
| US-12138583-B2 | Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring | AVPR2, HRH2, SLC43A1 | CACNA1H 2627/4885CARM1 1650/4885PRMT6 3019/4885 |
| US-20080280889-A1 | Inhibitors of Akt Activity | AKT2, PIK3CA, AKT1 | CACNA1H 4842/4885CARM1 2297/4885PRMT6 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.